Acquisition Details: Eli Lilly is acquiring Adverum Biotechnologies for up to $261.7 million to enhance its pipeline with the experimental eye disease treatment Ixo-vec, which targets wet age-related macular degeneration (wAMD).
Financial Terms: Lilly has offered $3.56 per share in cash, with potential milestone payments bringing the total to $12.47 per share, contingent on regulatory approval and sales targets.
Market Context: The wAMD treatment market is competitive, with existing therapies requiring frequent injections, while Ixo-vec aims to provide a one-time injection solution.
Future Outlook: Analysts predict significant sales potential for Ixo-vec, estimating global sales could reach $1.3 billion by 2033, and Lilly expects the acquisition to finalize in the fourth quarter.
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 218.110
Low
218.00
Averages
253.26
High
289.00
Current: 218.110
Low
218.00
Averages
253.26
High
289.00
Berenberg
Buy
maintain
$270 -> $275
2026-01-20
New
Reason
Berenberg
Price Target
$270 -> $275
AI Analysis
2026-01-20
New
maintain
Buy
Reason
Berenberg raised the firm's price target on AbbVie to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie's Skyrizi and Rinvoq citing an "exceptional" growth outlook.
Wedbush
Outperform
upgrade
$80 -> $147
2026-01-09
Reason
Wedbush
Price Target
$80 -> $147
2026-01-09
upgrade
Outperform
Reason
Wedbush raised the firm's price target on Revolution Medicines (RVMD) to $147 from $80 and keeps an Outperform rating on the shares. The firm notes that several news outlets have reported that Revolution is in talks with multiple parties to be acquired, including AbbVie (ABBV) and most recently Merck (MRK) who reported a valuation of between $28B and $32B was being discussed, but a deal was maybe not imminent and could take a few weeks to be finalized. Given the evolving news cycle, Wedbush is assuming the Financial Times report on Merck is likely accurate.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV
Unlock Now
Wolfe Research
Outperform -> Peer Perform
downgrade
2026-01-08
Reason
Wolfe Research
Price Target
2026-01-08
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded AbbVie to Peer Perform from Outperform.
Wolfe Research
Outperform -> Peer Perform
downgrade
2026-01-08
Reason
Wolfe Research
Price Target
2026-01-08
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded AbbVie to Peer Perform from Outperform without a price target. The firm believes the shares already reflect expectations for outperformance in Skyrizi and Rinvoq. Wolfe moves to the sidelines pending greater visibility on AbbVie's immunology and inflammation "encore" and competitive dynamics.
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
